0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Idiopathic Central Precocious Puberty in Girls as a Model of the Effect of Plasma Estradiol Level on Growth, Skeletal Maturation and Plasma Insulin-Like Growth Factor I

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Girls suffering from idiopathic central precocious puberty (CPP) may have different levels of estrogenic activity. This study was performed to evaluate the relationship between the estrogenic activity and the hypothalamopituitary activation and the effect of various plasma estradiol (E<sub>2</sub>) levels on growth, skeletal maturation and plasma insulin-like growth factor I (IGF-I). Fifty-eight girls with CPP were divided into 2 groups: group I with E<sub>2</sub> < 25 pg/ml (13 ± 1 pg/ml, mean ± SEM, n = 26) and group II with E2 ≧ 25 pg/ml (52 ± 3 pg/ml, n = 32). The mean ages at onset and at evaluation were lower in group I (5.9 ± 0.4 and 6.8 ± 0.4 years) than in group II (6.8 ± 0.3 and 8.1 ± 0.2 years, p < 0.01), but the durations since onset ( > 0.5 and < 2 years) in the two groups were similar. The mean peak luteinizing hormone/follicle-stimulating hormone (LH/FSH) ratios were lower in group I (0.8 ± 0.2) than in group II (1.7 ± 0.2, p < 0.001) and correlated with E<sub>2</sub> (r = 0.41, p < 0.01). The mean height gains during the year preceding the initial evaluation were similar in the two groups (8.7 ± 0.5 vs. 9.2 ± 0.4 cm). They were independent of the plasma E<sub>2</sub> level. Conversely, the mean plasma IGF-I values were lower in group I (2.4 ± 0.3 U/ml) than in group II (4.2 ± 0.6 U/ml, p < 0.01) and correlated with E<sub>2</sub>(r = 0.52, p < 0.01). They were in the prepubertal range in 88 % of cases in group I and in 35 % of cases in group II. The mean bone age advance was slightly but not significantly lower in group I (1.8 ± 0.3 years) than in group II (2.1 ± 0.2 years). We concluded that the correlation between E<sub>2</sub> and peak LH/FSH ratios indicates variable degrees of hypothalamopituitary-ovarian activation and that low E<sub>2</sub> stimulates growth in spite of prepubertal IGF-I values, suggesting a direct effect of E<sub>2</sub> on skeletal growth.

          Related collections

          Author and article information

          Journal
          HRE
          Horm Res Paediatr
          10.1159/issn.1663-2818
          Hormone Research in Paediatrics
          S. Karger AG
          978-3-8055-5597-5
          978-3-318-01985-8
          1663-2818
          1663-2826
          1991
          1991
          02 December 2008
          : 36
          : 3-4
          : 116-120
          Affiliations
          Unité d’Endocrinologie Pédiatrique, INSERM U 30, et Laboratoire de Physiologie, Faculté et Hôpital Necker Enfants Malades, Paris, France
          Article
          182143 Horm Res 1991;36:116–120
          10.1159/000182143
          1818007
          © 1991 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 5
          Categories
          Endocrinology of Puberty

          Comments

          Comment on this article